The development of highly effective and durable vaccines against the human malaria
parasites Plasmodium falciparum and P. vivax remains a key priority. Decades of endeavor …

Although there has been major recent progress in malaria vaccine development, substantial
challenges remain for achieving highly efficacious and durable vaccines against …

While recent progress has been made in reducing malaria mortality with other interventions,
vaccines are still urgently needed to further reduce the incidence of clinical disease …

The quest for a licensed effective vaccine against malaria remains a global priority. Even
though classical vaccine design strategies have been successful for some viral and bacterial …

Plasmodium falciparum malaria is a major global health problem, responsible for up to 1
million deaths each year. Major efforts have been made to develop an effective vaccine …

The development and implementation of a malaria vaccine would constitute a major
breakthrough for global health. Recently, numerous new candidates have entered clinical …

The concept of a malaria vaccine has sparked great interest for decades; however, the
challenge is proving to be a difficult one. Immune dysregulation by Plasmodium and the …

Several species of Plasmodium cause a broad spectrum of human disease that range from
nausea and fever to severe anemia, cerebral malaria, and multiorgan failure. In malaria …

After more than 50 years of intensive research and development, only one malaria vaccine
candidate,“RTS, S,” has progressed to Phase 3 clinical trials. Despite only partial efficacy …

Malaria—a parasite vector-borne disease—is a global health problem, and Plasmodium
falciparum has proven to be the deadliest among Plasmodium spp., which causes malaria in …